Paula T. Einhorn, MD, MS; William C. Cushman, MD; Paul K. Whelton, MB, MD, MSc; for the ALLHAT Collaborative Research Group
Disclaimer: Dr. Einhorn is a full-time employee of the National Heart, Lung, and Blood Institute. The views expressed in this letter do not necessarily represent the views of the National Heart, Lung, and Blood Institute; National Institutes of Health; or any other government entity.
Acknowledgment: The authors acknowledge scientific input from Drs. Jeffrey Cutler, Barry Davis, and Jackson Wright and administrative assistance from Dr. Ellen Breckenridge. The ALLHAT Collaborative Research Group was supported by contracts NO1-HC-35130 and HHSN268201100036C with the National Heart, Lung, and Blood Institute. The ALLHAT investigators acknowledge study medications contributed by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer.
Potential Conflicts of Interest: Dr. Cushman: Consultancy: Novartis, Takeda, AstraZeneca, Merck, Daiichi-Sankyo; Other: Dr. Cushman has received honoraria from Novartis and Takeda.
Einhorn PT, Cushman WC, Whelton PK, for the ALLHAT Collaborative Research Group. Chlorthalidone Versus Hydrochlorothiazide. Ann Intern Med. 2013;158:922–923. doi: 10.7326/0003-4819-158-12-201306180-00018
Download citation file:
Published: Ann Intern Med. 2013;158(12):922-923.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use